News

14

Mar, 2022

WHO Paediatric ARV dosing dashboard

Tags: , ,

The WHO have developed a Paediatric ARV dosing dashboard which aims to support health care workers, researchers and policy makers in decisions around ARV dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years old, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who want to investigate various ARV dosages and calculate the expected drug exposure in children relative to adult targets after administration of various doses. […]

READ MORE

1

Mar, 2022

Gap-f launches strategy plan!

Tags: ,

On March 1, 2022, the GAP-f network held a virtual event to launch its ambitious three-year strategy, spanning from 2022-2024. Through this event, the network solidified the WHO’s commitment to advancing health outcomes for children globally. GAP-f's three-year strategy (2022–2024) builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. The initial Phase I strategy focused on HIV, tuberculosis (TB) and hepatitis C products, and this new three-year strategy builds on the work undertaken in these disease areas, targeting additional therapeutic [...]
READ MORE

16

Jul, 2021

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children – A story by WHO

Tags: , ,

WHO welcomes new findings presented today at International Pediatric HIV Workshop on the superiority of dolutegravir (DTG)-based regimens in young children. Children living with HIV continue to be left behind by the global AIDS response. In 2020, only 54% of the 1.7 million children living with HIV received antiretroviral therapy in 2020 compared to 74% among adults living with HIV. Among the focus countries, only 40% of children living with HIV (or 74% of children receiving antiretroviral therapy) achieved viral suppression in 2020. The ODYSSEY trial, a multi-country randomised trial […]

READ MORE

2

Apr, 2021

Call for comments on the WHO Zika virus Research and Development Roadmap

Tags: ,

The WHO is calling on the public to share their comments on the newly drafted Zika virus Research and Development (R&D) Roadmap, a key component of the WHO’s R&D Blueprint which is a global strategy and preparedness plan that allows the activation of R&D activities in advance of and during pandemics. Comments can be submitted by completing this form. The Zika virus R&D roadmap aims to accelerate the development and implementation of effective medical countermeasures for the Zika virus so as to reduce morbidity, mortality and transmission of the virus. Zika is […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities

Subscribe

No thanks, I’m not interested!